HYLOMORPH AG

HYLOMORPH commercialises a platform technology for the solution of the problem of fibrotic encapsulation in implantable medical devices.

Fibrotic encapsulation threatens patients quality-of-life as it is responsible for complications such as revisions surgery in up to 1/3 plastic surgery patients and 5x increase major harms (including death) in pacemakers replacement. HYLOMOPRH is focusing on the core markets of breast surgery and cardiac stimulators, which together account for >4 million patients/year, for an addressable market opportunity of >1 billion USD.

We work in close collaboration with KOL end-users at Charité Berlin (one of the largest hospital centres in the world) for customer-centered product design and clinical development.

After successful pre-clinical proof-of-concept, our next great milestones are first-in-man clinical study in 2018 and CE mark and FDA approval of our first product in 2019.